Abiopharma

🔍 Sullivan Christopher Ryan (Executive)

Company: Avalo Therapeutics, Inc. (AVTX)

Report Date: 2026-05-06

Detailed Transactions and Holdings:

• Acquired 47,000 shares of Common Stock at $8.04 per share (Direct)
  Date: 2026-05-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 47,423.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 13,834 shares of Common Stock at $18.5525 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 33,589.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 12,347 shares of Common Stock at $19.2835 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 21,242.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 2,700 shares of Common Stock at $20.76 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 18,542.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 9,219 shares of Common Stock at $21.3698 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 9,323.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 8,900 shares of Common Stock at $22.5745 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 423.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 47,000 shares of Stock Option (Right to Buy) at $8.04 per share (Derivative)
  Date: 2026-05-06 | Code: M | Expires: 2035-01-28 | equity_swap_involved: 0 | shares_owned_after: 116,000.00 | transaction_form_type: 4 | Footnotes: F1, F7

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
• F2: The reported securities were sold in multiple transactions at prices ranging from $17.95 to $18.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F3: The reported securities were sold in multiple transactions at prices ranging from $19.02 to $19.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F4: The reported securities were sold in multiple transactions at prices ranging from $20.04 to $20.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F5: The reported securities were sold in multiple transactions at prices ranging from $21.10 to $21.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F6: The reported securities were sold in multiple transactions at prices ranging from $22.26 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F7: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.